Protein Modifications as Potential Biomarkers in Breast Cancer

Biomarker Insights

Volumn 4, Issue , 2009, Pages

  Jin, Hongjun ^a   Zangar, Richard C ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

biomarkers; breast cancer; post translational modifications; PTMs

Indexed keywords

EID: 77958186867     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S2557     Document Type: Review

References (142)

1. Golks A., Guerini D. The O-linked N-acetylglucosamine modification in cellular signalling and the immune system. ‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep. 2008 August; 9(8): 748–53.
2. Hoffman M.D., Sniatynski M.J., Kast J. Current approaches for global post-translational modification discovery and mass spectrometric analysis. Anal Chim Acta. 2008 October 3; 627(1): 50–61.
3. Janke C., Rogowski K., van D.J. Polyglutamylation: a fine-regulator of protein function? ‘Protein Modifications: beyond the usual suspects’ review series. EMBO Rep. 2008 July; 9(7): 636–41.
4. Krueger K.E., Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics. 2006 October; 5(10): 1799–810.
5. Hanash S.M., Pitteri S.J., Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature. 2008 April 3; 452(7187): 571–9.
6. Jensen O.N. Interpreting the protein language using proteomics. Nat Rev Mol Cell Biol. 2006 June; 7(6): 391–403.
7. Spickett C.M., Pitt A.R., Morrice N., Kolch W. Proteomic analysis of phosphorylation, oxidation and nitrosylation in signal transduction. Biochim Biophys Acta. 2006 December; 1764(12): 1823–41.
8. Chin L., Gray J.W. Translating insights from the cancer genome into clinical practice. Nature. 2008 April 3; 452(7187): 553–63.
9. Sawyers C.L. The cancer biomarker problem. Nature. 2008 April 3; 452(7187): 548–52.
10. Sawyers C.L. Cancer: mixing cocktails. Nature. 2007 October 25; 449(7165): 993–6.
11. Souza J.M., Peluffo G., Radi R. Protein tyrosine nitration—functional alteration or just a biomarker? Free Radic Biol Med. 2008 August 15; 45(4): 357–66.
12. Tesarova P., Kalousova M., Trnkova B. et al. Carbonyl and oxidative stress in patients with breast cancer—is there a relation to the stage of the disease? Neoplasma. 2007; 54(3): 219–24.
13. Beckman J.S. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann NY Acad Sci. 1994 November 17; 738: 69–75.
14. Beckman J.S., Chen J., Ischiropoulos H., Crow J.P. Oxidative chemistry of peroxynitrite. Methods Enzymol. 1994; 233: 229–40.
15. Beckman J.S., Chen J., Crow J.P., Ye Y.Z. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res. 1994; 103: 371–80.
16. Lange C.A., Sartorius C.A., Bdel-Hafiz H., Spillman M.A., Horwitz K.B., Jacobsen B.M. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol. 2008; 630: 94–111.
17. Ouchi T. BRCA1 phosphorylation: biological consequences. Cancer Biol Ther. 2006 May; 5(5): 470–5.
18. Glover J.N., Williams R.S., Lee M.S. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem Sci. 2004 November; 29(11): 579–85.
19. Vazquez-Martin A., Oliveras-Ferraros C., Colomer R., Brunet J., Menendez J.A. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann Oncol. 2008 June; 19(6): 1097–109.
20. Cui Y., Parra I., Zhang M. et al. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 June 1; 66(11): 5950–9.
21. Ouyang X., Gulliford T., Zhang H., Smith G., Huang G., Epstein R.J. Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer. Mol Cell Biochem. 2001 February; 218(1-2): 47–54.
22. Atsriku C., Britton D.J., Held J.M. et al. Systematic mapping of posttranslational modifications in human estrogen receptor alpha, with emphasis on novel phosphorylation sites. Mol Cell Proteomics. 2008 November 3.
23. Duong V., Bret C., Altucci L. et al. Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res. 2008 December; 6(12): 1908–19.
24. Popov V.M., Wang C., Shirley L.A. et al. The functional significance of nuclear receptor acetylation. Steroids. 2007 February; 72(2): 221–30.
25. Fu M., Wang C., Zhang X., Pestell R.G. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol. 2004 September 15; 68(6): 1199–208.
26. Margueron R., Duong V., Bonnet S. et al. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol. 2004 April; 32(2): 583–94.
27. Wang C., Fu M., Angeletti R.H. et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem. 2001 May 25; 276(21): 18375–83.
28. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 2001; 491: 369–402.
29. Kumar S.R., Sauter E.R., Quinn T.P., Deutscher S.L. Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection. Clin Cancer Res. 2005 October 1; 11(19 Pt 1): 6868–71.
30. Croce M.V., Segal-Eiras A. The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer. Drugs Today (Bare). 2002 November; 38(11): 759–68.
31. Tu L., Tai W.C., Chen L., Banfield D.K. Signal-mediated dynamic retention of glycosyltransferases in the Golgi. Science. 2008 July 18; 321(5887): 404–7.
32. Maccioni H.J. Glycosylation of glycolipids in the Golgi complex. J Neurochem. 2007 November;103 Suppl 1: 81–90.
33. Czlapinski J.L., Bertozzi C.R. Synthetic glycobiology: Exploits in the Golgi compartment. Curr Opin Chem Biol. 2006 December; 10(6): 645–51.
34. Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005 June; 4(6): 477–88.
35. Newsom-Davis T.E., Wang D., Steinman L. et al. Enhanced immune recognition of cryptic glycan markers in human tumors. Cancer Res. 2009 March 1; 69(5): 2018–25.
36. Bosques C.J., Raguram S., Sasisekharan R. The sweet side of biomarker discovery. Nat Biotechnol. 2006 September; 24(9): 1100–1.
37. Lau K.S., Dennis J.W. N-Glycans in cancer progression. Glycobiology. 2008 October; 18(10): 750–60.
38. Soleimani L., Roder J.C., Dennis J.W., Lipina T. Beta N-acetylglucosaminyl transferase V (Mgat5) deficiency reduces the depression-like phenotype in mice. Genes Brain Behav. 2008 April; 7(3): 334–43.
39. Dennis J.W., Granovsky M., Warren C.E. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1999 December 6; 1473(1): 21–34.
40. Dennis J.W., Laferte S., Waghorne C., Breitman M.L., Kerbel R.S. Beta 1–6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science. 1987 May 1; 236(4801): 582–5.
41. Kim Y.J., Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 1997 August; 14(5): 569–76.
42. bd Hamid U.M., Royle L., Saldova R. et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology. 2008 December; 18(12): 1105–18.
43. Sozzani P., Arisio R., Porpiglia M., Benedetto C. Is Sialyl Lewis x antigen expression a prognostic factor in patients with breast cancer? Int J Surg Pathol. 2008 October; 16(4): 365–74.
44. Zen K., Liu D.Q., Guo Y.L. et al. CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS ONE. 2008; 3(3): e1826.
45. Julien S., Grimshaw M.J., Sutton-Smith M. et al. Sialyl-Lewis(x) on P-selectin glycoprotein ligand-1 is regulated during differentiation and maturation of dendritic cells: a mechanism involving the glycosyltransferases C2GnT1 and ST3Gal I. J Immunol. 2007 November 1; 179(9): 5701–10.
46. Jeschke U., Mylonas I., Shabani N. et al. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res. 2005 May; 25(3A): 1615–22.
47. Kumamoto K., Mitsuoka C., Izawa M. et al. Specific detection of sialyl Lewis X determinant carried on the mucin GlcNAcbeta1—>6GalNAcal-pha core structure as a tumor-associated antigen. Biochem Biophys Res Commun. 1998 June 18; 247(2): 514–7.
48. Gilewski T.A., Ragupathi G., Dickler M. et al. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res. 2007 May 15; 13(10): 2977–85.
49. Sewell R., Backstrom M., Dalziel M. et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem. 2006 February 10; 281(6): 3586–94.
50. Miles D., Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer. 2003 February;3 Suppl 4: S134–8.
51. Julien S., Krzewinski-Recchi M.A., Harduin-Lepers A. et al. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5 Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J. 2001 November; 18(11-12): 883–93.
52. Leivonen M., Nordling S., Lundin J., von B.K., Haglund C. STn and prognosis in breast cancer. Oncology. 2001; 61(4): 299–305.
53. Soares R., Marinho A., Schmitt F. Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters. Pathol Res Pract. 1996 December; 192(12): 1181–6.
54. Schindlbeck C., Stellwagen J., Jeschke U. et al. Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen. Clin Exp Metastasis. 2008; 25(3): 233–40.
55. Storr S.J., Royle L., Chapman C.J. et al. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology. 2008 June; 18(6): 456–62.
56. Schindlbeck C., Jeschke U., Schulze S. et al. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients. Breast Cancer Res Treat. 2007 January; 101(1): 17–25.
57. Heimburg J., Yan J., Morey S. et al. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia. 2006 November; 8(11): 939–48.
58. Wolf M.F., Ludwig A., Fritz P., Schumacher K. Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. Tumour Biol. 1988; 9(4): 190–4.
59. Springer G.F., Murthy M.S., Desai P.R., Scanlon E.F. Breast cancer patient's cell-mediated immune response to Thomsen-Friedenreich (T) antigen. Cancer. 1980 June 15; 45(12): 2949–54.
60. Madjd Z., Parsons T., Watson N.F., Spendlove I., Ellis I., Durrant L.G. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. Breast Cancer Res. 2005; 7(5): R780–7.
61. Clarke K., Lee F.T., Brechbiel M.W., Smyth F.E., Old L.J., Scott A.M. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res. 2000 September; 6(9): 3621–8.
62. Capurro M., Bover L., Portela P., Livingston P., Mordoh J. FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis(x) hapten. Cancer Immunol Immunother. 1998 February; 45(6): 334–9.
63. Chang W.W., Lee C.H., Lee P. et al. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc Natl Acad Sci USA. 2008 August 19; 105(33): 11667–72.
64. Wang C.C., Huang Y.L., Ren C.T. et al. Glycan microarray of Globo H and related structures for quantitative analysis of breast cancer. Proc Natl Acad Sci USA. 2008 August 19; 105(33): 11661–6.
65. Huang C.Y., Thayer D.A., Chang A.Y. et al. Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc Natl Acad Sci USA. 2006 January 3; 103(1): 15–20.
66. Gilewski T., Ragupathi G., Bhuta S. et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci USA. 2001 March 13; 98(6): 3270–5.
67. Sanders R.D., Allen D.N., Forman D., Tarpey T., Keshavan M.S., Goldstein G. Confirmatory factor analysis of the Neurological Evaluation Scale in unmedicated schizophrenia. Psychiatry Res. 2005 January 30; 133(1): 65–71.
68. Lin E.Y., Pollard J.W. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004 June 1; 90(11): 2053–8.
69. Lin E.Y., Pollard J.W. Macrophages: modulators of breast cancer progression. Novartis Found Symp. 2004; 256: 158–68.
70. Thornalley P.J. Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans. 2003 December; 31(Pt 6): 1372–7.
71. Karihtala P., Winqvist R., Syvaoja J.E., Kinnula V.L., Soini Y. Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. Eur J Cancer. 2006 October; 42(15): 2653–9.
72. Karihtala P., Kinnula V.L., Soini Y. Antioxidative response for nitric oxide production in breast carcinoma. Oncol Rep. 2004 October; 12(4): 755–9.
73. Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science. 2004 November 5; 306(5698): 966–8.
74. Karihtala P., Mantyniemi A., Kang S.W., Kinnula V.L., Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003 August 15; 9(9): 3418–24.
75. Karihtala P., Soini Y., Auvinen P., Tammi R., Tammi M., Kosma V.M. Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem. 2007 December; 55(12): 1191–8.
76. Murillo M.M., Carmona-Cuenca I., Del C.G. et al. Activation of NADPH oxidase by transforming growth factor-beta in hepatocytes mediates up-regulation of epidermal growth factor receptor ligands through a nuclear factor-kappaB-dependent mechanism. Biochem J. 2007 July 15; 405(2): 251–9.
77. Clempus R.E., Griendling K.K. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res. 2006 July 15; 71(2): 216–25.
78. Kim J., Lin J., Adam R.M., Lamb C., Shively S.B., Freeman M.R. An oxidative stress mechanism mediates chelerythrine-induced heparin-binding EGF-like growth factor ectodomain shedding. J Cell Biochem. 2005 January 1; 94(1): 39–49.
79. Chiarugi P., Fiaschi T. Redox signalling in anchorage-dependent cell growth. Cell Signal. 2007 April; 19(4): 672–82.
80. Fruehauf J.P., Meyskens F.L. Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 2007 February 1; 13(3): 789–94.
81. Giannoni E., Buricchi F., Raugei G., Ramponi G., Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol. 2005 August; 25(15): 6391–403.
82. Steiner C., Peters W.H., Gallagher E.P., Magee P., Rowland I., Pool-Zobel B.L. Genistein protects human mammary epithelial cells from benzo(a)pyrene-7, 8-dihydrodiol-9,10-epoxide and 4-hydroxy-2-nonenal genotoxicity by modulating the glutathione/glutathione S-transferase system. Carcinogenesis. 2007 March; 28(3): 738–48.
83. Albright C.D., Klem E., Shah A.A., Gallagher P. Breast cancer cell-targeted oxidative stress: enhancement of cancer cell uptake of conjugated linoleic acid, activation of p53, and inhibition of proliferation. Exp Mol Pathol. 2005 October; 79(2): 118–25.
84. Kuo P.L., Chen C.Y., Tzeng T.F., Lin C.C., Hsu Y.L. Involvement of reactive oxygen species/c-Jun NH(2)-terminal kinase pathway in kotomolide A induces apoptosis in human breast cancer cells. Toxicol Appl Pharmacol. 2008 June 1; 229(2): 215–26.
85. Kabat G.C., Rohan T.E. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control. 2007 December; 18(10): 1047–53.
86. Khan G.N., Merajver S.D. Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency. Curr Pharm Des. 2007; 13(35): 3584–90.
87. Brandon M., Baldi P., Wallace D.C. Mitochondrial mutations in cancer. Oncogene. 2006 August 7; 25(34): 4647–62.
88. Rajneesh C.P., Manimaran A., Sasikala K.R., Adaikappan P. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J. 2008 August; 49(8): 640–3.
89. Kumaraguruparan R., Subapriya R., Viswanathan P., Nagini S. Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast. Clin Chim Acta. 2002 November; 325(1-2): 165–70.
90. Buser K., Joncourt F., Altermatt H.J., Bacchi M., Oberli A., Cerny T. Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol. 1997 April; 8(4): 335–41.
91. Gromadzinska J., Wasowicz W., Andrijewski M. et al. Glutathione and glutathione metabolizing enzymes in tissues and blood of breast cancer patients. Neoplasma. 1997; 44(1): 45–51.
92. Todorova V.K., Harms S.A., Luo S., Kaufmann Y., Babb K.B., Klimberg V.S. Oral glutamine (AES-14) supplementation inhibits PI-3k/Akt signaling in experimental breast cancer. JPEN J Parenter Enteral Nutr. 2003 November; 27(6): 404–10.
93. Tesarova P., Kalousova M., Jachymova M., Mestek O., Petruzelka L., Zima T. Receptor for advanced glycation end products (RAGE)—soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007 December; 25(8): 720–5.
94. Lopez-Sanchez L.M., Muntane J., de la M.M., Rodriguez-Ariza A. Unraveling the S-nitrosoproteome: tools and strategies. Proteomics. 2009 February; 9(4): 808–18.
95. Arnold J.N., Saldova R., Hamid U.M., Rudd P.M. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008 August; 8(16): 3284–93.
96. Kumar G.K., Prabhakar N.R. Post-translational modification of proteins during intermittent hypoxia. Respir Physiol Neurobiol. 2008 December 10; 164(1-2): 272–6.
97. Temporini C., Calleri E., Massolini G., Caccialanza G. Integrated analytical strategies for the study of phosphorylation and glycosylation in proteins. Mass Spectrom Rev. 2008 May; 27(3): 207–36.
98. Wiesner J., Premsler T., Sickmann A. Application of electron transfer dissociation (ETD) for the analysis of posttranslational modifications. Proteomics. 2008 November; 8(21): 4466–83.
99. Bigelow D.J. Nitrotyrosine-modified SERCA2: a cellular sensor of reactive nitrogen species. Pflugers Arch. 2009 January; 457(3): 701–10.
100. Wu S., Lourette N.M., Tolic N. et al. An Integrated Top-Down and Bottom-Up Strategy for Broadly Characterizing Protein Isoforms and Modifications. J Proteome Res. 2009 February 10.
101. Bigelow D.J., Qian W.J. Quantitative proteome mapping of nitrotyrosines. Methods Enzymol. 2008; 440: 191–205.
102. Livesay E.A., Tang K., Taylor B.K. et al. Fully automated four-column capillary LC-MS system for maximizing throughput in proteomic analyses. Anal Chem. 2008 January 1; 80(1): 294–302.
103. Marginean I., Kelly R.T., Prior D.C., LaMarche B.L., Tang K., Smith R.D. Analytical characterization of the electrospray ion source in the nanoflow regime. Anal Chem. 2008 September 1; 80(17): 6573–9.
104. Smallwood H.S., Lourette N.M., Boschek C.B. et al. Identification of a denitrase activity against calmodulin in activated macrophages using high-field liquid chromatography—FTICR mass spectrometry. Biochemistry. 2007 September 18; 46(37): 10498–505.
105. Yang Z.P., Harris L.E., Palmer-Toy D.E., Hancock W.S. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clinical Chemistry. 2006 October; 52(10): 1897–905.
106. Barciszewska A.M., Murawa D., Gawronska I., Murawa P., Nowak S., Barciszewska M.Z. Analysis of 5-methylcytosine in DNA of breast and colon cancer tissues. IUBMB Life. 2007 December; 59(12): 765–70.
107. Marx C., Yau C., Banwait S. et al. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol. 2007 June; 71(6): 1525–34.
108. Kato I., Chen G., Djuric Z. Non-steroidal anti-inflammatory drug (NSAID) use and levels of a lipid oxidation marker in plasma and nipple aspirate fluids. Breast Cancer Res Treat. 2006 May; 97(2): 145–8.
109. Yamazaki H., Inoue T., Koizumi M. et al. Urinary 8-hydroxy-2'-deoxyguanosine excretion as a biomarker for estimating DNA oxidation in patients undergoing external radiotherapy and/or brachytherapy. Oncol Rep. 2005 May; 13(5): 847–51.
110. Cao Y., Karsten U., Hilgers J. Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues. Tumour Biol. 1998; 19 Suppl 1: 88–99.
111. Kirmiz C., Li B., An H.J. et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics. 2007 January; 6(1): 43–55.
112. Kyselova Z., Mechref Y., Kang P. et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008 July; 54(7): 1166–75.
113. Rexhepaj E., Brennan D.J., Holloway P. et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res. 2008; 10(5): R89.
114. Yasuoka H., Tsujimoto M., Yoshidome K. et al. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer. 2008 November 23; 8(1): 340.
115. Chen S., LaRoche T., Hamelinck D. et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods. 2007 May; 4(5): 437–44.
116. Zhou B., Phan V., Liu X., Juhasz A., Chu P.G., Yen Y. Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues. Hybridoma (Larchmt). 2006 October; 25(5): 264–70.
117. Li C., Simeone D.M., Brenner D.E. et al. Pancreatic Cancer Serum Detection Using a Lectin/Glyco-Antibody Array Method. J Proteome Res. 2009 February 6; 8(2): 483–92.
118. Zangar R.C., Varnum S.M., Covington C.Y., Smith R.D. A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarray. Dis Markers. 2004; 20(3): 135–48.
119. Varnum S.M., Covington C.C., Woodbury R.L. et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat. 2003 July; 80(1): 87–97.
120. Woodbury R.L., Varnum S.M., Zangar R.C. Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. J Proteome Res. 2002 May; 1(3): 233–7.
121. Yaziji H., Taylor C.R., Goldstein N.S. et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008 December; 16(6): 513–20.
122. Tomonaga T., Matsushita K., Yamaguchi S. et al. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res. 2004 March 15; 10(6): 2007–14.
123. Sikut R., Zhang K., Baeckstrom D., Hansson G.C. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast-cancer patients. Int J Cancer. 1996 May 29; 66(5): 617–23.
124. Martersteck C.M., Kedersha N.L., Drapp D.A., Tsui T.G., Colley K.J. Unique alpha 2, 8-polysialylated glycoproteins in breast cancer and leukemia cells. Glycobiology. 1996 April; 6(3): 289–301.
125. Zhang S., Cordon-Cardo C., Zhang H.S. et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer. 1997 September 26; 73(1): 42–9.
126. Cribb A.E., Knight M.J., Dryer D. et al. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev. 2006 March; 15(3): 551–8.
127. Bransfield L.A., Rennie A, Visvanathan K. et al. Formation of two novel estrogen guanine adducts and HPLC/MS detection of 4-hydroxyestradiol-N7-guanine in human urine. Chem Res Toxicol. 2008 August; 21(8): 1622–30.
128. Samozu M., Brennan M.L., To V. et al. Association between nitrotyrosine levels and microvascular density in human breast cancer. Breast Cancer Res Treat. 2002 June; 74(3): 271–8.
129. Nakamura Y., Yasuoka H., Tsujimoto M. et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res. 2006 February 15; 12(4): 1201–7.
130. Yakovlev V.A., Barani I.J., Rabender C.S. et al. Tyrosine nitration of Ikap-paBalpha: a novel mechanism for NF-kappaB activation. Biochemistry. 2007 October 23; 46(42): 11671–83.
131. Agnoletto M.H., Guecheva T.N., Donde F. et al. Association of low repair efficiency with high hormone receptors expression and SOD activity in breast cancer patients. Clin Biochem. 2007 November; 40(16-17): 1252–8.
132. Joshi G., Hardas S., Sultana R., St Clair D.K., Vore M., Butterfield D.A. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemo-brain. J Neurosci Res. 2007 February 15; 85(3): 497–503.
133. Gouaze V., ndrieu-Abadie N., Cuvillier O. et al. Glutathione peroxidase-1 protects from CD95-induced apoptosis. J Biol Chem. 2002 November 8; 277(45): 42867–74.
134. Citardi M.J., Song W., Batra P.S., Lanza D.C., Hazen S.L. Characterization of oxidative pathways in chronic rhinosinusitis and sinonasal polyposis. Am J Rhinol. 2006 May; 20(3): 353–9.
135. Wu R.C., Smith C.L., O'Malley B.W. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocrine Reviews. 2005 May; 26(3): 393–9.
136. Zheng F.H.F., Wu R.C., Smith C.L., O'Malley B.W. Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Molecular and Cellular Biology. 2005 September; 25(18): 8273–84.
137. Pfister S., Rea S., Taipale M. et al. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 2008 March 15; 122(6): 1207–13.
138. Feng W., Lu Z., Luo R.Z. et al. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer. 2007 April 15; 120(8): 1664–8.
139. Pledgie-Tracy A., Sobolewski M.D., Davidson N.E. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther. 2007 March; 6(3): 1013–21.
140. Krusche C.A., Wulfing P., Kersting C. et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005 March; 90(1): 15–23.
141. Miura Y., Hato M., Shinohara Y. et al. BlotGIycoABC (TM), an integrated glycoblotting technique for rapid and large scale clinical glycomics. Molecular and Cellular Proteomics. 2008 February; 7(2): 370–7.
142. Iwahana H., Yakymovych I., Dubrovska A., Hellman U., Souchelnytskyi S. Glycoproteome profiling of transforming growth factor-beta (TGF beta) signaling: Nonglycosylated cell death-inducing DFF-like effector A inhibits TGF beta 1-dependent apoptosis. Proteomics. 2006 December; 6(23): 6168–80.